WHAT IS CLAIMED IS:

1. A pharmaceutical formulation, comprising:

(i) an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1; a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; and a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6; and

(ii) a surfactant at an amount below the critical micelle concentration (CMC) of said surfactant, wherein the surfactant is not polysorbate 20 (PS20).

2. The pharmaceutical formulation of claim 1, wherein the surfactant is polysorbate 80 (PS80), poloxamer, a Brij series surfactant, or tocopheryl polyethylene glycol succinate (TPGS).

3. The pharmaceutical formulation of claim 1 or 2, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising SEQ ID NO:7 and a light chain variable region comprising SEQ ID NO:8.

4. The pharmaceutical formulation of any one of claims 1-3, wherein the antibody or antigen binding fragment thereof comprises a heavy chain comprising SEQ ID NO:9 and a light chain comprising SEQ ID NO:10.

5. The pharmaceutical formulation of any one of claims 1-4, comprising from about 2 mg/mL to about 200 mg/mL of the antibody or antigen binding fragment thereof.

6. The pharmaceutical formulation of any one of claims 1-5, comprising from about 2 mg/mL to about 150 mg/mL of the antibody or antigen binding fragment thereof, optionally comprising about 150 mg/mL of the antibody or antigen binding fragment thereof.

7. The pharmaceutical formulation of any one of claims 1-6, comprising from about 2 mg/mL to about 100 mg/mL of the antibody or antigen binding fragment thereof.

8. The pharmaceutical formulation of any one of claims 1-7, comprising about 30 mg/mL of the antibody or antigen binding fragment thereof.

9. The pharmaceutical formulation of any one of claims 1-8, wherein the amount of surfactant is at least about 10% below, at least 20% below, at least 30% below, at least 40% below, at least 50% below, at least 60% below, at least 70% below, at least 80% below, at least 90% below, at least 95% below, at least 96% below, at least 97% below, at least 98% below, or at least 99% below the CMC of said surfactant.

10. The pharmaceutical formulation of any one of claims 1-9, wherein the surfactant is PS80 at an amount of from about 0.0004% (w/v) to about 0.0012% (w/v), optionally at 0.0004% (w/v), 0.0012% (w/v), or 0.006% (w/v).

11. The pharmaceutical formulation of any one of claims 1-9, wherein the surfactant is TPGS at an amount of from about 0.001% (w/v) to about 0.02% (w/v).

12. The pharmaceutical formulation of any one of claims 1-9, wherein the surfactant is a Brij series surfactant at an amount of from about 0.001% (w/v) to about 0.01% (w/v).

13. The pharmaceutical formulation of any one of claims 1-9, wherein the surfactant is PS20 at an amount of about 0.006% (w/v).

14. The pharmaceutical formulation of any one of claims 1-9, wherein the surfactant is poloxamer at an amount of from about 0.027% (w/v) to about 0.08% (w/v).

15. The pharmaceutical formulation of any one of claims 1-9, wherein the surfactant is poloxamer at an amount of from about 0.03% (w/v) to about 0.08% (w/v).

16. The pharmaceutical formulation of claim 14 or 15, wherein the poloxamer is poloxamer 188.

17. The pharmaceutical formulation of any one of claims 1-16, further comprising (iii) an uncharged excipient.

18. The pharmaceutical formulation of claim 17, comprising from about 20 mM to about 80 mM of the uncharged excipient.

19. The pharmaceutical formulation of claim 17, comprising from about 200 mM to about 400 mM of the uncharged excipient.

20. The pharmaceutical formulation of any one of claims 17-19, comprising from about 1.5% (w/v) to about 8.5% (w/v) of the uncharged excipient.

21. The pharmaceutical formulation of any one of claims 17-20, wherein the uncharged excipient is fructose, glucose, mannose, sorbose, xylose, lactose, maltose, sucrose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, trehalose, sorbitol, erythritol, isomalt, lactitol, maltitol, xylitol, glycerol, lactitol, hydroxyethyl starch, water-soluble glucan, or a combination thereof.

22. The pharmaceutical formulation of claim 21, wherein the uncharged excipient is sucrose, optionally about 250 mM sucrose.

23. The pharmaceutical formulation of claim 21, wherein the uncharged excipient is trehalose.

24. The pharmaceutical formulation of any one of claims 17-20, wherein the uncharged excipient is mannitol, optionally about 250 mM mannitol.

25. The pharmaceutical formulation of any one of claims 1-24, further comprising (iv) arginine.

26. The pharmaceutical formulation of any one of claims 1-25, further comprising (v) histidine.

27. The pharmaceutical formulation of claim 26, comprising from about 15 mM to about 30 mM histidine.

28. The pharmaceutical formulation of any one of claims 1-27, further comprising a buffer.

29. The pharmaceutical formulation of claim 28, wherein the buffer is acetate.

30. The pharmaceutical formulation of claim 28, wherein the buffer is succinate.

31. The pharmaceutical formulation of any one of claims 1-30, wherein the pH of the formulation is about 5.5 to about 6.0.

32. The pharmaceutical formulation of claim 31, wherein the pH of the formulation is about 5.5.

33. The pharmaceutical formulation of claim 31, wherein the pH of the formulation is about 5.6.

34. A pharmaceutical formulation, comprising:

(i) about 2 mg/mL to about 100 mg/mL of an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1; a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6; and

(ii) about 0.0004% (w/v) to about 0.0012% (w/v) PS80, or about 0.03% (w/v) to about 0.08% (w/v) poloxamer.

35. The pharmaceutical formulation of claim 34, further comprising:

(iii) about 1.5% (w/v) to about 8.5% (w/v) trehalose;

(iv) about 100 mM to about 200 mM L-arginine; and

(v) about 15 mM to about 30 mM histidine.

36. A pharmaceutical formulation, comprising:

(i) about 2 mg/mL to about 100 mg/mL of an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1; a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light chain

variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6;

(ii) about 0.0004% (w/v) PS80, about 0.0012% (w/v) PS80, about 0.03% (w/v) poloxamer or about 0.08% (w/v) poloxamer;

(iii) about 250 mM trehalose;

(iv) about 130 mM L-arginine; and

(v) about 20 mM histidine.

37. A pharmaceutical formulation, comprising:

(i) about 30 mg/mL of an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1 a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6;

(ii) about 0.0004% (w/v) PS80, about 0.0012% (w/v) PS80, about 0.03% (w/v) poloxamer 188, or about 0.08% (w/v) poloxamer 188;

(iii) about 250 mM trehalose;

(iv) about 130 mM L-arginine; and

(v) about 20 mM histidine.

38. A pharmaceutical formulation, comprising:

(i) about 2 mg/mL to about 200 mg/mL of an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1 a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light

chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6;

(ii) about 0.006% (w/) PS20, about 0.0004% (w/v) PS80, about 0.0012% (w/v) PS80, about 0.006% (w/v) PS80, about 0.08% (w/v) poloxamer, or about 0.27% (w/v) poloxamer;

(iii) about 250 mM sucrose; and

(iv) acetate.

39. A pharmaceutical formulation, comprising:

(i) about 2 mg/mL to about 200 mg/mL of an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1 a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6;

(ii) about 0.006% (w/) PS20, about 0.0004% (w/v) PS80, about 0.0012% (w/v) PS80, about 0.006% (w/v) PS80, about 0.08% (w/v) poloxamer, or about 0.27% (w/v) poloxamer;

(iii) about 250 mM sucrose; and

(iv) succinate.

40. A pharmaceutical formulation, comprising:

(i) about 2 mg/mL to about 200 mg/mL of an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1 a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6;

(ii) about 0.006% (w/) PS20, about 0.0004% (w/v) PS80, about 0.0012% (w/v) PS80, about 0.006% (w/v) PS80, about 0.08% (w/v) poloxamer, or about 0.27% (w/v) poloxamer;

(iii) about 250 mM mannitol; and

(iv) acetate.

41. A pharmaceutical formulation, comprising:

(i) about 2 mg/mL to about 200 mg/mL of an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:1 a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2; a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3; a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4; a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5; and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:6;

(ii) about 0.006% (w/) PS20, about 0.0004% (w/v) PS80, about 0.0012% (w/v) PS80, about 0.006% (w/v) PS80, about 0.08% (w/v) poloxamer, or about 0.27% (w/v) poloxamer;

(iii) about 250 mM mannitol; and

(iv) succinate.

42. The pharmaceutical formulation of any one of claims 38-41 comprising about 150 mg/mL of the antibody or antigen binding fragment thereof.

43. The pharmaceutical formulation of any one of claims 38-41 comprising about 2 mg/mL to about 100 mg/mL of the antibody or antigen binding fragment thereof

44. The pharmaceutical formulation of any one of claims 38-41 comprising about 30 mg/mL of the antibody or antigen binding fragment thereof.

45. The pharmaceutical formulation of any one of claims 1-44, wherein the pharmaceutical formulation is stable following aggressive agitation for about 10 days at room temperature.

46. The pharmaceutical formulation of claim 45, wherein the pharmaceutical formulation has less than 20 subvisible particles per mL.

47. The pharmaceutical formulation of any one of claims 1-46, wherein the pharmaceutical formulation has about 20% less, about 30% less, about 40% less, about 50% less, about 60% less, about 70% less, about 80% less, about 90% less, about 95% less, or about 99% less subvisible particles following from about 1 to about 7 freeze-thaw cycles.

48. The pharmaceutical formulation of any one of claims 1-47, wherein the pharmaceutical formulation has about 20% less, about 30% less, about 40% less, about 50% less, about 60% less, about 70% less, about 80% less, about 90% less, about 95% less, or about 99% less subvisible particles following storage for about 1 month at about 40˚C.

49. The pharmaceutical formulation of any one of claims 1-48, suitable for intravenous, subcutaneous, or intramuscular administration.

50. The pharmaceutical formulation of any one of claims 1-49, wherein the pharmaceutical formulation is a liquid pharmaceutical formulation.

51. The pharmaceutical formulation of any one of claims 1-49, wherein the pharmaceutical formulation is a lyophilized pharmaceutical formulation.

52. A dosage form comprising the pharmaceutical formulation of any one of claims 1-51 in a container.

53. The dosage form of claim 52, wherein the container is a plastic vial or glass vial.

54. The dosage form of claim 52, wherein the container is a pre-filled syringe.

55. The dosage form of claim 54, wherein the pre-filled syringe comprises a needle.

56. The dosage form of claim 55, wherein the needle is a 29G thin wall needle.

57. The dosage form of any one of claims 54-56, wherein the pre-filled syringe is a plastic syringe or a glass syringe.

58. The dosage form of any one of claims 54-57, wherein the pre-filled syringe is coated with silicone.

59. A kit, comprising the pharmaceutical formulation of any one of claims 1-51 or the dosage form of any one of claims 52-58 and instructions for use.

60. Use of the pharmaceutical formulation of any one of claims 1-51 or the dosage form of any one of claims 52-58 in the manufacture of a medicament for treating a pulmonary disease or disorder in a subject, wherein a therapeutically effective amount of the pharmaceutical formulation or the dosage form is to be administered to the subject.

61. The use of claim 60, wherein the pulmonary disease or disorder is an eosinophilic disease or disorder.

62. The use of claim 60, wherein the pulmonary disease or disorder is asthma, chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis, acute and chronic eosinophilic bronchitis, acute and chronic eosinophilic pneumonia, Churg-Strauss syndrome, hypereosinophilic syndrome, drug, irritant and radiation-induced pulmonary eosinophilia, infection-induced pulmonary eosinophilia, autoimmune-related pulmonary eosinophilia, eosinophilic esophagitis, Crohn's disease, or a combination thereof.

63. The use of claim 60, wherein the pulmonary disease or disorder is asthma.

64. The use of claim 63, wherein the asthma is eosinophilic asthma, neutrophilic asthma, combined eosinophilic and neutrophilic asthma, or aspirin sensitive asthma.

65. The pharmaceutical formulation of any one of claims 1-51 or the dosage form of any one of claims 52-58 for therapy.